Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017

Data Examining RBX2660 Treatment in Relation to “Healthy” Gut Microbiome, Placebo Response Rates in a Meta Analysis and Microbiome Engraftment to be Showcased


Download this press release (158 KB).

ROSEVILLE, MN (June 01, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present three posters during the American Society for Microbiology’s ASM Microbe 2017, being held June 1-5, 2017 in New Orleans. One poster will be part of the general poster sessions, and two will be highlighted as “Poster Talks,” where they will be presented orally with an opportunity to take questions from the audience. The posters include data analyses from clinical studies featuring RBX2660, Rebiotix’s Phase 3-ready broad spectrum microbiota suspension designed to rehabilitate the human microbiome by delivering live microbes into a patient’s intestinal tract to treat disease.

The schedule of Rebiotix-focused presentations at ASM Microbe 2017 is as follows:

Investigators

K. Blount, C. Jones, B. Shannon, S. Carter

Date & Time

Saturday, June 3rd, 12:15 PM – 2:15 PM, CT

Session & Location

193-AAID08 – Infection Prevention and Control: Treatment and Prevention of Clostridium Difficile Infection – Ernest N. Morial Convention Center

Investigators

D. Gerding, C. Jones, K. Blount, B. Shannon

Day & Time

Sunday, June 4th; 1:15 PM – 1:25 PM, CT

Session & Location

Hot News on Epidemiology and Management of C. difficile infection – Ernest N. Morial Convention Center

Investigators

A. Ray, C. Jones, B. Shannon, S. Carter

Day & Time

Sunday, June 4th; 1:45 PM – 1:55 PM, CT

Session & Location

Hot News on Epidemiology and Management of C. difficile infection – Ernest N. Morial Convention Center


About Rebiotix Inc.

Rebiotix Inc. is a clinical-stage microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its lead drug candidate, RBX2660, expected to enter Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection.  RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s clinical pipeline also features RBX7455, a room temperature stable oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection.  In addition, Rebiotix is targeting several other disease indications with drug products built on its pioneering Microbiota Restoration Therapy (MRT) platform.  MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:

Jason Rando
Tiberend Strategic Advisors
212-375-2665
jrando@nulltiberend.com